REPL - Replimune Group, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Replimune Group, Inc.

18 Commerce Way
Woburn, MA 01801
United States
781-995-2443
http://www.replimune.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees62

Key Executives

NameTitlePayExercisedYear Born
Mr. Philip Astley-SparkeExec. Chairman, Sec. & Treasurer338.45kN/A1971
Dr. Robert CoffinPres, CEO & Director536.29kN/A1965
Dr. Colin LoveChief Operating Officer413.62kN/A1958
Dr. Pamela EspositoChief Bus. Officer351.45kN/A1974
Stephen GorgolChief Accounting OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.